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A B S T R A C T
Objective: Maternal obesity and metabolic health affect pregnancy outcomes. We examined whether
maternal metabolic profiles are associated with placental and fetal hemodynamics.
Study Design: In a population-based prospective cohort study among 1175 women we examined the
associations of an adverse maternal metabolic profile in early pregnancy with placental, fetal cerebral
and cardiac hemodynamic development. We obtained maternal pre-pregnancy BMI by questionnaire and
measured blood pressure, cholesterol, triglycerides and glucose concentrations at a median gestational
age of 12.6 (95 % range 9.6–17.1) weeks. An adverse maternal metabolic profile was defined as 4 risk
factors. Placental and fetal hemodynamics were measured by pulsed-wave-Doppler at a median
gestational age of 30.3 (95 % range 28.8–32.3) weeks.
Results: An adverse maternal metabolic profile was associated with a 0.29 Z-score higher (95 %CI
0.080.50) fetal cerebral middle artery pulsatility index (PI), but not with placental or fetal cardiac
hemodynamic patterns. When the individual components of an adverse maternal metabolic profile were
assessed, we observed that higher maternal total cholesterol and triglyceride concentrations were
associated with a higher cerebral middle artery PI (Z-score, 0.09 (95 %CI 0.020.15), 0.09 (95 %CI
0.030.15) per Z-score increase). Higher total and HDL maternal cholesterol concentrations were also
associated with a higher aorta ascendens peak systolic velocity (PSV) Z-score, 0.08 (95 %CI 0.010.14)),
and a larger left cardiac output (Z-score, 0.08 (95 %CI 0.000.15), respectively).
Conclusion: An adverse maternal metabolic profile, especially higher cholesterol and triglycerides
concentrations, are associated with increased fetal cerebral vascular resistance and larger fetal aorta
ascendens diameter, PSV and left cardiac output, but not with placental vascular resistance indices.
Further studies are needed to identify long-term consequences of the observed associations.
© 2020 Elsevier B.V. All rights reserved.
Introduction
Maternal pre-pregnancy obesity is strongly related to metabolic
disturbances during pregnancy, including insulin resistance, an
adverse cholesterol profile and high triglycerides concentrations
[1,2]. Both maternal pre-pregnancy obesity and these subsequent
metabolic disturbances are major risk factors for pregnancy
complications and adverse cardiovascular outcomes in offspring
[3]. The mechanisms by which maternal pre-pregnancy obesity
leads to adverse fetal and childhood outcomes might involve
suboptimal early placental development leading to placental and
fetal hemodynamic alterations [4].
Several studies have shown that maternal pre-pregnancy
obesity, gestational diabetes and hyperlipidemia are associated
with larger placental weight at birth [5–7]. An adverse maternal
metabolic profile may also lead to a pro-inflammatory state leading
to reduced placental vascularization, placental infarction and
reduced placenta growth [8]. Placental weight is only a crude
measure of placental development and function during pregnancy.
Utero-placental and feto-placental peripheral vascular resistance
can be assessed by Doppler ultrasound of the uterine and umbilical
arteries throughout pregnancy. Altered vascular resistance in the
main placental arteries may subsequently lead to changes in blood
circulation of the brain and heart of the fetus.
We hypothesized that an adverse maternal early-pregnancy
metabolic profile affects early placental development leading to
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ethods
esign and study population
This study was embedded in the Generation R Study, a
opulation-based, prospective cohort study from fetal life onwards
n Rotterdam, the Netherlands [9,10]. The Medical Ethics Commit-
ee of the Erasmus MC, University Medical Center, Rotterdam, had
pproved the study (2001). All children were born between April
002 and January 2006. Detailed assessments of fetal and
hildhood growth and development were conducted in a random
ubgroup of 1232 Dutch mothers and children [11]. For the current
nalyses, twin pregnancies (n = 15), and pregnancies leading to
erinatal death (n = 2) were excluded from this analyses, resulting
n 1215 singleton live born children. First trimester maternal
etabolic profile measurements and third trimester placental and
etal hemodynamic patterns were available in 1175 mothers and
heir children (Fig. 1).
aternal metabolic profile
At enrollment, we measured maternal height (cm) without
hoes and clothing. Information about maternal weight just
efore pregnancy was obtained by questionnaire. We calculated
MI (kg/m2). First trimester blood pressure and blood samples
ere collected at a median gestational age of 12.6 (95 % range
.6–17.1) weeks, as described in detail [12,13]. Briefly, blood
ressure measurements were performed when participants
ere seated in upright position with back support and were
sked to relax for 5 min. A cuff was placed around the non-
ominant upper arm, which was supported at the level of the
eart, with the bladder midline over the brachial artery
ulsation. In case of an upper arm exceeding 33 cm, a larger
uff (32–42 cm) was used. The mean value of two BP readings
ver a 60-second interval was documented for each participant
14,15]. All non-fasting blood samples were transported to a
edicated laboratory facility in Rotterdam, the Netherlands
STAR-MDC). Processing was aimed to finish within a maximum
f 3 h after sampling and stored at 80 C. Total cholesterol,
HDL-cholesterol, triglycerides and glucose concentrations are
enzymatic assays and were measured with c702 module on the
Cobas 8000 analyzer [13]. As a measure of a metabolic syndrome
like phenotype, we defined an adverse maternal metabolic
profile as  4 of the following risk factors; BMI higher than 25.0,
blood pressure, total cholesterol, triglycerides and glucose
concentrations belonging to the highest 25 % of our study
population or HDL-cholesterol concentrations belonging to the
lowest 25 % of our study population (16).
Third trimester placental and fetal hemodynamic characteristics
Utero-placental and feto-placental peripheral vascular resis-
tance were assessed by pulsed-wave Doppler at a median
gestational age of 30.3 (95 % range 28.8–32.3) weeks, as described
previously [17,18].
Uterine artery resistance index (RI) was measured in the uterine
arteries near the crossover with the external iliac artery. Umbilical
artery pulsatility index (PI) was determined in a free-floating loop
of the umbilical cord. A higher uterine RI and umbilical artery PI
indicated a higher peripheral vascular resistance [19,20]. Middle
cerebral artery Doppler measurements were obtained in the
proximal part of the cerebral arteries. The middle cerebral artery PI
quantifies the redistribution of blood flow, and when lower, in
favor of the fetal brain. Reductions in middle cerebral artery PI is a
valid indicator of fetal circulatory redistribution [21,22]. An
indicator of the ‘brain-sparing effect’ is a raised ratio between
the umbilical artery PI and the cerebral artery PI (U/C ratio) [23].
Cardiac flow-velocity waveforms at the level of the mitral valves
were recorded from the apical 4-chamber view of the fetal heart.
Peak velocities of the E wave and the A wave, were recorded. The E/
A ratio, which is an index for ventricular diastolic function and
expresses both cardiac compliance and preload conditions, was
calculated [18]. Cardiac outflow flow-velocity waveforms from the
aorta were recorded from the 5-chamber view and the short-axis
view of the fetal heart just above the semi-lunar valves,
respectively. Peak systolic velocity (PSV) and the inner diameter
during systole were recorded. Left cardiac output was calculated in
milliliters per minute by multiplying the vessel area by the time-
velocity integral by fetal heart rate. All ultrasound examinations
were performed with an ATL-Philips model HDI 5000 (Seattle,
Washington, USA) equipped with a 5.0-MHz high-frequency,
curved-array transducer.Fig. 1. Flow chart of participants included in the analysis.
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We obtained information on maternal educational level,
parity, and smoking during pregnancy from multiple
questionnaires during pregnancy by the mother. Third trimes-
ter estimated fetal weight was obtained during ultrasound
[24]. Infant sex was obtained from midwife and hospital
registries.
Statistical analyses
First, we assessed the associations of an adverse maternal early-
pregnancy metabolic profile with placental, fetal cerebral and
cardiac hemodynamics using multiple linear regression models.
The models were adjusted for maternal age, educational level,
parity, smoking status during pregnancy, third trimester gesta-
tional age, estimated fetal weight and child sex. We also performed
a sensitive analysis using birth weight instead estimated fetal
weight. Next, we examined the associations of each of the
individual components of an adverse maternal early-pregnancy
metabolic profile with placental, fetal cerebral and cardiac
hemodynamics using similar models. For interpretation purposes,
we also presented these associations in a graph which shows
standardized predicted values for these associations obtained from
the regression models. For the associations of maternal early-
pregnancy blood pressure, cholesterol, triglycerides and glucose
concentrations with placental and fetal hemodynamic measures,
we further explored whether the associations were explained by
maternal pre-pregnancy BMI. We also tested potential interaction
between maternal metabolic factors and BMI for all of our analyses.
Table 1
Characteristics of mothers and their children after multiple imputation.
Maternal characteristics
Total group (N = 1.175) Mothers with an adverse metabolic
profile (N = 108, 9.2%)
Mothers without an adverse
metabolic profile (N = 728, 62%)
P-value
Maternal age 31.9 (22.0–39.1) 32.4 (23.6–39.5) 31.8 (21.4–39.0) 0.7
Education (%) <0.001
Low (no, primary, secondary education) 36.9 (434) 50.9 (55) 33.2 (242)
High (higher education) 63.1 (741) 49.1 (53) 66.8 (486)
Pre-pregnancy body mass index (kg/m2) 23.5 (4.0) 28.5 (5.0) 22.7 (3.2) <0.001
BMI > 25.0 22.4 (263) 80.6 (87) 17.7 (129) <0.001
Parity (%) 0.8
Nullipara 60.8 (714) 61.1 (66) 62.6 (456)
Multipara 39.2 (461) 38.9 (42) 37.4 (272)
Smoking during pregnancy (%) 0.3
No smoking throughout pregnancy 76.1 (894) 73.1 (79) 77.7 (567)
Yes 23.9 (281) 26.9 (29) 22.3 (161)
Gestational hypertension (%) 6.0 (71) 12 (11.1) 37 (5.1) 0.03
Pre-eclampsia (%) 2.3 (27) 5.6 (6) 3.0 (22) 0.04
First trimester maternal characteristics
Gestational age at measurement, weeks 12.6 (9.6–17.1) 12.9 (9.5–17.0) 12.8 (9.7–17.1) 0.7
Systolic blood pressure (mmHg) 119 (13) 134 (12) 116 (11) <0.001
Diastolic blood pressure (mmHg) 70 (10) 80 (10) 68 (9) <0.001
Total cholesterol, mmol/L 4.9 (0.9) 5.4 (0.9) 4.8 (0.8) <0.001
HDL-cholesterol, mmol/L 1.8 (0.3) 1.6 (0.3) 1.8 (0.3) <0.001
Triglycerides, mmol/L 1.3 (0.5) 1.8 (0.6) 1.2 (0.4) <0.001
Glucose mmol/L 4.4 (0.8) 4.9 (1.0) 4.3 (0.8) <0.001
Third trimester fetal characteristics
Sex 0.1
Male 52.4 (616) 59.3 (64) 51.0 (371)
Female 47.6 (559) 40.7 (44) 49.0 (357)
Gestational age at measurement, weeks 30.3 (27.4–32.6) 30.2 (28.6–32.3) 30.4 (28.4–32.7) <0.01
Estimated fetal weight, grams 1628 (268) 1609 (265) 1624 (275) 0.6
Third trimester feto-placental hemodynamics
Uterine artery RI 0.49 (0.08) 0.49 (0.08) 0.49 (0.07) 0.9
Umbilical artery PI 0.97 (0.17) 0.97 (0.16) 0.97 (0.17) 0.6
Third trimester fetal cerebral hemodynamics
Middle cerebral artery PI 1.97 (0.33) 2.07 (0.30) 1.96 (0.34) <0.01
Umbilical/Middle cerebral artery ratio 0.50 (0.11) 0.48 (0.09) 0.51 (0.12) <0.01
Third trimester fetal cardiac hemodynamics
Aorta ascendens diameter (cm) 0.64 (0.07) 0.64 (0.07) 0.65 (0.07) 0.4
Aorta ascendens PSV (cm/s) 91.3 (12.4) 92.1 (13.6) 91.1 (12.6) 0.5
Left cardiac output (ml/min) 606 (173) 593 (165) 615 (183) 0.3
Mitral valve E/A ratio 0.78 (0.10) 0.78 (0.09) 0.78 (0.10) 0.9
Birth characteristics
Mode of Delivery (%) <0.01
Vaginal, spontaneous 69.6 (818) 57.4 (62) 70.3 (512)
Vaginal, delivery induced 10.5 (123) 20.4 (22) 10.2 (74)
Cesarean section 13.1 (154) 18.5 (20) 12.1 (88)
Unknown 9.5 (80) 3.7 (4) 7.4 (54)
Apgar score (5 min), % 9.6 (0.8) 9.5 (0.8) 9.6 (0.8) 0.1
Gestational age at birth, weeks 40.3 (35.9–42.4) 40.0 (34.7–42.4) 40.3 (35.9–42.4) 0.6
Preterm birth (<37 weeks), % 4.2 (49) 4.6 (5) 4.0 (29) 0.8
Birth weight, g 3517 (541) 3539 (584) 3499 (529) 0.5
Low birth weight (<2500 g), % 3.9 (46) 4 (3.7) 3.7 (27) 0.9
Values are means (standard deviation), medians (95 % range) or valid percentages (absolute numbers). RI: resistance index, PI: pulsatility index, PSV: Peak Systolic Volume.
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nalyses were performed. Finally, we examined the associations of
hange in maternal weight and blood pressure from early-
regnancy until 30 weeks of pregnancy with third trimester
lacental, fetal cerebral and cardiac hemodynamics using the same
ultiple linear regression models. The percentages of missing
ovariate values within the population for analyses was lower than
3 %. Missing covariate data were imputed using the multiple
mputations procedure (n = 5 imputations) and the imputed
atasets were analyzed together. No major differences in the effect
stimates were observed between analyses with imputed missing
ata and complete cases only (data not shown). All measures of
ssociations are presented within their 95 % confidence intervals
(CI). Statistical analyses were performed using SPSS version 24.0
for Windows (SPSS Inc., Chicago, Illinois, USA).
Results
Participants characteristics
Table 1 shows the population characteristics. 22.5 % of the
mothers were overweight or obese at the start of pregnancy and
9.2 % of the mothers had an adverse metabolic profile at the start of
their pregnancy. During pregnancy 6.0 % and 2.3 % of the mothers
developed gestational hypertension and pre-eclampsia, respec-
tively. The median gestational age was 40.3 (35.9–42.4) and theFig. 2. Associations of maternal adverse metabolic profile with third trimester placental (a), fetal cerebral (b) and fetal cardiac hemodynamics (c).
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shows the participant characteristics before multiple imputation.
Third trimester placental hemodynamics
Fig. 2a shows no associations were present of an adverse
maternal metabolic profile with uterine artery RI and umbilical
artery PI. Similarly, none of the individual components of an
adverse maternal metabolic profile were associated with placental
hemodynamics (Table 2, Figure S1).
Third trimester fetal cerebral hemodynamics
Mothers with an adverse metabolic profile had a 0.29 (95 % CI
0.08, 0.50) Z-score increase in the fetal cerebral middle artery PI
compared to mothers without an adverse metabolic profile
(Fig. 2b). When we assessed the individual components of an
adverse maternal metabolic profile separately, higher total
maternal cholesterol and triglyceride concentrations were associ-
ated with a higher cerebral middle artery PI (Table 3, Figure S2 Z-
score, 0.09 (95 % CI 0.02, 0.15), 0.09 (95 % CI 0.03, 0.15) per Z-score
increase in total cholesterol and triglyceride concentrations,
respectively). These associations were not explained by maternal
BMI. No associations of maternal pre-pregnancy BMI, blood
pressure, HDL-cholesterol and glucose concentrations with fetal
cerebral hemodynamics were present. The associations with the
fetal U/C ratio were similar (Fig. 2, Table 2).
Third trimester fetal cardiac hemodynamics
An adverse maternal metabolic profile was not associated with
fetal cardiac hemodynamics (Fig. 2c). When we assessed the
associations of individual components of an adverse maternal
metabolic profile with fetal cardiac hemodynamics, a higher
maternal diastolic blood pressure, total and HDL-cholesterol
concentrations were associated with a higher fetal left cardiac
output (Table 4, Z-score 0.08 (95 % CI 0.02, 0.15), 0.07 (95 % CI 0.01,
0.13), 0.11 (95 % CI 0.05, 0.18) per Z-score increase in diastolic blood
pressure, total and HDL-cholesterol concentrations, respectively).
Higher maternal HDL-cholesterol concentrations were associated
with a larger aorta ascendens diameter and aorta ascendens PSV
(Z-score 0.10 (95 % CI 0.04, 0.17), 0.08 (95 % CI 0.01, 0.14) per Z-score
increase in HDL-cholesterol concentrations). Total maternal
cholesterol concentrations were also associated with a higher
aorta ascendens PSV (Z-score 0.08 (95 % CI 0.01, 0.14) per Z-score
increase in total cholesterol concentrations). These associations
were not explained by adjustment for maternal pre-pregnancy
BMI. No associations of maternal triglyceride or glucose
concentrations with fetal cardiac hemodynamics were present.
Similar findings were present when we used birth weight instead
of estimated fetal weight (results not shown). For visual
interpretation we showed in Figure S3 the standardized regression
prediction values of the multiple linear regression models of
maternal pre-pregnancy BMI, total cholesterol, triglyceride and
glucose concentrations with third trimester fetal cardiac hemody-
namics in graph format. Table 5 shows that maternal weight gain
was associated with a larger aorta ascendens diameter and an
increase in cardiac output (Z-score 0.02 (95 % CI 0.01, 0.04) and 0.02
(95 % CI 0.01, 0.04) per increase in weight gain, respectively).
Higher increase in maternal systolic blood pressure was associated
with a higher uterine artery RI and umbilical artery PI (Z-score
0.09, (95 % CI 0.03, 0.15) and 0.08 (95 % CI 0.02, 0.15) per increase in
blood pressure, respectively) and a decrease in aorta ascendens
diameter and left cardiac output (Z-score -0.07 (95 % CI -0.13, -0.01)
and -0.07 (95 % CI -0.13, -0.01) per increase in blood pressure),
whereas a higher increase in diastolic blood pressure was




In this population prospective cohort study we observed that an
adverse maternal early-pregnancy metabolic profile, especially
higher maternal cholesterol and triglycerides concentrations, were
associated with increased fetal cerebral vascular resistance and
larger fetal aorta ascendens diameter, PSV and left cardiac output,
but not with placental vascular resistance indices. These associ-
ations were not explained by maternal BMI.
Interpretation
Maternal pre-pregnancy obesity is strongly related to metabolic
disturbances during pregnancy [1,2]. Both maternal pre-pregnancy
obesity and these subsequent metabolic disturbances are major
risk factors for pregnancy complications and adverse birth
outcomes [3]. The underlying mechanisms are not known, but
might be related to impaired placental growth and function [4].
The placenta can be considered as the interface between the
maternal and fetal environment and the major regulator of fetal
nutrition, growth and cardiovascular development [25]. Multiple
studies have shown that maternal obesity is related to larger
placental weight [26]. Several studies also showed that individual
components of an adverse maternal metabolic profile, such as high
blood pressure, high triglycerides, adverse cholesterol profile and
high glucose concentrations are associated with both low and high
placental weight at birth [27–29], which suggest various mecha-
nisms may be involved. An adverse maternal metabolic profile may
lead to a pro-inflammatory state leading to reduced placental
vascularization, placental infarction and reduced placenta growth,
whereas an adverse maternal metabolic profile may also lead to
increased nutrient transfer to the placental, larger placental
growth and accelerate fetal growth [8].
Placental weight is only a crude measurement of placental
development and function during pregnancy. More detailed
measures of placental function can be assessed by Doppler
ultrasound of the umbilical and uterine arteries during pregnancy.
Table 2
Associations of early pregnancy maternal BMI, blood pressure and first trimester
metabolic concentrations with third trimester utero-placental and feto-placental
hemodynamics (n = 1175).
Uterine artery RI
Z-score (95 % CI)
Umbilical artery PI
Z-score (95 % CI)
Pre-pregnancy BMI (Z-score) 0.06 (-0.00, 0.12) 0.06 (-0.01, 0.12)
Systolic blood pressure (Z-score) 0.07 (-0.01, 0.16) 0.00 (-0.06, 0.06)
Diastolic blood pressure (Z-score) 0.01 (-0.05, 0.08) 0.01 (-0.07, 0.06)
Total cholesterol (Z-score) 0.03 (-0.09, 0.03) 0.00 (-0.06, 0.06)
HDL-cholesterol (Z-score) 0.00 (-0.07, 0.06) 0.05 (-0.11, 0.01)
Triglycerides (Z-score) 0.01 (-0.07, 0.05) 0.05 (-0.02, 0.11)
Glucose (Z-score) 0.06 (-0.01, 0.12) 0.01 (-0.07, 0.06)
Values are regression coefficients (95 % confidence intervals) and reflect the change
in Z-score of placental indexes per Z-score change in maternal BMI, blood pressure
and metabolic concentrations. The models are adjusted for maternal age,
educational level, parity, smoking status during pregnancy, third trimester
gestational age and estimated fetal weight, and child sex. RI: resistance index,
PI: pulsatility index.
5
A higher uterine RI and umbilical artery PI indicated a higher
peripheral vascular resistance [19,20]. We observed no associa-
tions of maternal metabolic profile with the uterine and umbilical
artery vascular resistance. A few other studies explored the
associations of individual components of an adverse maternal
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31 women affected by hypertensive disorders showed a higher
terine artery PI compared with normative pregnancies [30].
mong 10 women with familial hypercholesterolemia, it was
bserved that the PI of the uterine arteries was similar at 24 weeks
f gestation, and remained unaltered at 36 weeks of gestation, in
ontrast to a decrease in the reference group [31]. An intervention
tudy among 290 pregnant women demonstrate a more pro-
ounced gestational decrease in the umbilical artery PI between 24
nd 30 weeks of pregnancy after following a low-cholesterol low-
population. We studied women with relatively healthy pregnan-
cies and assessed associations across the full range of maternal
metabolic factors, whereas many of the previous studies focused
on high-risk populations and women with clinically abnormal
metabolic parameters, such as clinical hypercholesterolemia. This
may suggest that associations with uterine and umbilical vascular
resistance are only present at the extremes of these adverse
maternal metabolic factors, but not across the full range.
Consequences of impaired placentation might lead to redistribu-
tion of blood flow, with increased fetal blood to the brain and heart of
able 3
ssociations of early pregnancy maternal BMI, blood pressure, and first trimester metabolic concentrations with third trimester fetal cerebral hemodynamics (n = 1175).
Cerebral middle artery
PI Z-score (95% CI)
Umbilical/Cerebral middle artery PI ratio
Z-score (95 % CI)
Pre-pregnancy BMI (Z-score) 0.05 (-0.01, 0.12) 0.01 (-0.07, 0.06)
Systolic blood pressure (Z-score) 0.05 (-0.01, 0.12) 0.03 (-0.09, 0.03)
Diastolic blood pressure (Z-score) 0.05 (-0.02, 0.11) 0.03 (-0.09, 0.04)
Total cholesterol (Z-score) 0.09 (0.02, 0.15)† 0.07 (-0.13, -0.01)*
+pre-pregnancy BMI 0.08 (0.02, 0.15)* 0.07 (-0.13, -0.01)*
HDL-cholesterol (Z-score) 0.04 (-0.10, 0.03) 0.02 (-0.09, 0.04)
Triglycerides (Z-score) 0.09 (0.03, 0.15)† 0.03 (-0.10, 0.03)
+pre-pregnancy BMI 0.09 (0.02, 0.15)†
Glucose (Z-score) 0.02 (-0.04, 0.09) 0.02 (-0.09, 0.04)
alues are regression coefficients (95 % confidence intervals) and reflect the change in Z-score of fetal cerebral indexes per Z-score change in maternal BMI, blood pressure and
etabolic concentrations. The models are adjusted for maternal age, educational level, parity, smoking status during pregnancy, third trimester gestational age and estimated
tal weight, and child sex. PI: pulsatility index. *=P<0.05, †=P<0.01.
able 4
ssociations of early pregnancy maternal BMI, blood pressure and first trimester metabolic concentrations with third trimester fetal cardiac hemodynamics (n = 1175).
Aorta ascendens diameter
Z-score (95 % CI)
Aorta ascendens PSV
Z-score (95 % CI)
Left cardiac output
Z-score (95 % CI)
Mitral valve E/A ratio
Z-score (95 % CI)
Pre-pregnancy BMI (Z-score) 0.02 (-0.09, 0.04) 0.00 (-0.07, 0.07) 0.03 (-0.10, 0.04) 0.01 (-0.05, 0.08)
Systolic blood pressure (Z-score) 0.01 (-0.06, 0.07) 0.00 (-0.07, 0.07) 0.01 (-0.06, 0.07) 0.03 (-0.03, 0.09)
Diastolic blood pressure (Z-score) 0.04 (-0.02, 0.10) 0.03 (-0.04, 0.09) 0.08 (0.02, 0.15)† 0.01 (-0.05, 0.07)
+pre-pregnancy BMI 0.12 (0.05, 0.20)†
Total cholesterol (Z-score) 0.02 (-0.04, 0.08) 0.08 (0.01, 0.14)* 0.07 (0.01, 0.13)* 0.01 (-0.08, 0.05)
+pre-pregnancy BMI 0.08 (0.01, 0.15)* 0.07 (0.01, 0.14)*
HDL-cholesterol (Z-score) 0.10 (0.04, 0.17)† 0.08 (0.01, 0.14)* 0.11 (0.05, 0.18)† 0.05 (-0.11, 0.02)
+pre-pregnancy BMI 0.10 (0.04, 0.16)† 0.07 (0.00, 0.14)* 0.11 (0.04, 0.17)†
Triglycerides (Z-score) 0.03 (-0.10, 0.03) 0.04 (-0.03, 0.10) 0.01 (-0.06, 0.07) 0.00 (-0.06, 0.07)
Glucose (Z-score) 0.01 (-0.07, 0.05) 0.05 (-0.02, 0.11) 0.02 (-0.08, 0.05) 0.05 (-0.12, 0.02)
alues are regression coefficients (95 % confidence intervals) and reflect the change in Z-score of fetal cardiac hemodynamics per Z-score change in maternal BMI, blood
ressure and metabolic concentrations. The models are adjusted for maternal age, educational level, parity, smoking status during pregnancy, third trimester gestational age
nd estimated fetal weight, and child sex. PSV: Peak Systolic Volume. *=P<0.05, †=P<0.01.
able 5
ssociations of maternal weight gain during pregnancy, and third trimester blood pressure with third trimester fetal placental, cerebral and cardiac hemodynamics (n = 1175).
Maternal weight gain
during pregnancy
Maternal third trimester systolic
blood pressure (Z-score)
Maternal third trimester diastolic
blood pressure (Z-score)
Uterine artery RI, Z-score (95 % CI) 0.00 (-0.01, 0.01) 0.09 (0.03, 0.15)† 0.05 (-0.01, 0.11)
Umbilical artery PI, Z-score (95 % CI) 0.00 (-0.02, 0.01) 0.08 (0.02, 0.15)† 0.06 (0.00, 0.12)*
Cerebral middle artery PI, Z-score (95 % CI) 0.01 (-0.02, 0.01) 0.03 (-0.03, 0.09) 0.04 (-0.02, 0.10)
Aorta ascendens diameter, Z-score (95 % CI) 0.02 (0.01, 0.04)* 0.07 (-0.13, -0.01)* 0.01 (-0.05, 0.07)
Aorta ascendens PSV, Z-score (95 % CI) 0.01 (-0.02, 0.01) 0.02 (-0.09, 0.04) 0.04 (-0.11, 0.02)
Left cardiac output, Z-score (95 % CI) 0.02 (0.01, 0.04)† 0.07 (-0.13, -0.01)* 0.00 (-0.06, 0.06)
Mitral valve E/A ratio, Z-score (95 % CI) 0.00 (-0.01, 0.02) 0.02 (-0.08, 0.04) 0.01 (-0.05, 0.07)
alues are regression coefficients (95 % confidence intervals) and reflect the change in Z-score of fetal hemodynamics per change in maternal weight gain and z-score change
 blood pressure. The models are adjusted for maternal age, educational level, parity, smoking status during pregnancy, third trimester gestational age and estimated fetal
eight, and child sex. PSV: Peak Systolic Volume. *=P<0.05, †=P<0.01.aturated fat diet [32]. Two studies among Chilean women showed
 correlation of total- and LDL-cholesterol concentrations, but not
riglyceride concentrations, with lower sensitivity of the umbilical
ein rings and reactivity, a phenomena that is likely due to
ndothelial dysfunction [33,34]. Differences between our study
nd previous studies may be explained by differences in study6
the fetus due to reduced oxygen supply and its influence on fetal
vascular development. The middle cerebral artery PI quantifies the
redistribution of blood flow, and when lower, in favor of the fetal
brain. An indicator of the ‘brain-sparing effect’ is a raised ratio
between the umbilical artery PI and the cerebral artery PI (U/C ratio)
[23]. In line with previous studies from the same cohort we used the
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cerebral artery PI/umbilical artery PI ratio. These measurements
have aninverse1:1 correlation [35–37].Tothe bestof ourknowledge,
not many data on fetal hemodynamic reference data are available
and they describe different populations which makes comparisons
difficult [38]. However, our study is focused on the associations of
maternal metabolic factors with fetal hemodynamic parameters in
which we show differences in these fetal hemodynamic parameters
by maternal metabolic factors. Further studies are needed to
replicate our findings in different populations and to examine the
effects on absolute values of the fetal hemodynamic parameters.We
observed that an adverse maternal early-pregnancy metabolic
profile was associated with increased fetal cerebral vascular
resistance. These associations were mainly present for high
cholesterol and triglyceride concentrations. Higher cholesterol
concentrations were also associated with a larger fetal left cardiac
output, larger aorta ascendens diameter and larger aorta ascendens
PSV. Our findings thus suggest that increased maternal cholesterol
and triglycerides levels, still within the normal range (reference
range total cholesterol concentrations, women 50th centile 5.0 (95 %
range 3.3–7.3), triglyceride concentrations, 50th centile 1.0 (95 %
range 0.4–2.9) (39)), lead to increased fetal cerebral resistance
indexes and aorta ascendens diameter, aorta ascendens PSV and
cardiac output suggesting a ‘reverse’ redistribution in favor of
increased cardiac growth. The findings were not explained by
maternal BMI, suggesting effects of maternal cholesterol and
triglyceride concentrations within the normal range were indepen-
dent of BMI. In line with our findings, results from the same study
cohort also showed that maternal triglyceride and cholesterol levels
are associated with increased fetal growth rates which resulted in a
higher birth weight [40]. These findings might suggest that these
increased maternal lipid levels have consequences for fetal cardiac
development and might lead to persistent subclinical consequences
in childhood. Longitudinal studies reported tracking of risk factors
for cardiovascular disease during childhood [41,42]. Also the
consequences of fetal adaptations might not be detectable during
fetal life, but might become more evident in early adulthood. It had
been suggested that fetal adaptations can be compensated for many
years until for example hypertension occurs [43]. No other previous
studies explored the associations of maternal cholesterol or
triglycerides concentrations with fetal cerebral vascular resistance
or fetal cardiac hemodynamics. However, the effect estimates are
small and are mainly relevant on a population level providing further
insight into pathophysiological mechanisms. Further studies are
needed to replicate our findings, to explore these associations
throughout pregnancy and to assess the consequences for both birth
outcomes and long-term offspring outcomes.
Strengths and limitations
The main strength of this study is the large population-based
cohort studied. To our knowledge, this is the largest study, which
examined the effects of maternal metabolic factors on placental
and fetal hemodynamics. The population-based setting enabled us
to assess maternal metabolic factors and placental and fetal
hemodynamic measures across the full range, rather than only in
mothers or fetuses with complications. However, because of our
relatively healthy population, it should be further studied whether
the observed associations are generalizable to high-risk popula-
tions. We observed that increased weight gain was associated with
maternal BMI and blood pressure with third trimester fetal
hemodynamics. We only measured maternal glucose, cholesterol
and triglyceride concentrations once during pregnancy. However,
it has been suggested that impaired glucose control in early
pregnancy persists throughout pregnancy [44]. Similarly, choles-
terol and triglyceride concentrations are elevated during all three
trimesters of pregnancy in women with gestational diabetes [45].
Further studies are needed with repeat maternal glucose and lipids
concentrations measurements throughout pregnancy to replicate
our findings and to identify the critical periods for feto-placental
hemodynamic adaptations. In the present study, we evaluated
multiple associations; this might have led to chance findings due to
multiple testing. However, because of the correlations between the
fetal hemodynamic measures we did not correct for multiple
testing. Missing fetal hemodynamic measurements could lead to
selection bias and loss of power. Our results would be biased if the
associations between maternal metabolic factors and fetal
hemodynamics differ between those included and those not
included in the study. Although this seems unlikely, it cannot be
excluded. Finally, although we had information about a large
number of confounders, the influence of residual confounding
should be considered, as in any observational study.
Conclusions
An adverse maternal metabolic profile, especially higher
maternal cholesterol and triglycerides concentrations still within
the normal range, were associated with increased fetal cerebral
vascular resistance and increased fetal cardiac hemodynamics, but
not with placental vascular resistance indices.
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